Acute myeloid leukemia: 2014 update on risk-stratification and management.

Abstract excerpt

OVERVIEW: Evidence suggests that even patients aged 70 or above benefit from specific AML therapy. The fundamental decision in AML then becomes whether to recommend standard or investigational treatment. This decision must rest on the likely outcome of standard treatment. Hence we review factors that predict treatment related mortality and resistance to therapy, the latter the principal cause of failure even in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Allografts
• Share to Cause of Death
• Share to Combined Modality Therapy